Pfizer and Project Veritas

Undercover video released by Project Veritas on Wednesday shows a high-level employee at pharmaceutical giant Pfizer spilling company secrets about the company’s controversial — and potentially illegal — virological research, as well as other ethically questionable business practices.

In the video, Jordon Trishton Walker, Pfizer Director of Research and Development, Strategic Operations, talks candidly about Pfizer’s work on COVID-19 and vaccines. Walker appears to believe he’s on a date, but the man he’s talking to is one of Project Veritas’s undercover journalists.

At one point in the video, Walker describes research the company is conducting that seems to resemble the controversial practice called “gain of function,” in which researchers modify viruses to imbue them with new qualities or capabilities.

“One of the things we’re exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right? So, we have to do that. If we’re gonna do that though, there’s a risk of like, as you could imagine — no one wants to be having a pharma company mutating f**king viruses,” Walker said.

“Don’t tell anyone. Promise you won’t tell anyone. The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them,” he said.

Later in the video, Walker also suggests that top employees at Pfizer know that COVID-19 did not originate organically — or at they very least, they’re skeptical of that theory.

“You have to be very controlled to make sure that this virus [COVID] that you mutate doesn’t create something that just goes everywhere. Which, I suspect, is the way that the virus started in Wuhan, to be honest. It makes no sense that this virus popped out of nowhere,” he said. “It’s bullsh*t”

More from Walker: “From what I’ve heard is they [Pfizer scientists] are optimizing it [COVID mutation process], but they’re going slow because everyone is very cautious — obviously they don’t want to accelerate it too much. I think they are also just trying to do it as an exploratory thing because you obviously don’t want to advertise that you are figuring out future mutations.”

In the video, Walker denies that Pfizer is conducting gain-of-function research, and he instead calls the practice used by Pfizer scientists “directed evolution.”

Project Veritas is a controversial non-profit that conducts undercover journalism. The group is run by James O’Keefe, a conservative provocateur who rose to national stardom with undercover sting operations targeting left-wing activists. The more recent targets of Project Veritas’s work have included large social media companies, CNN, and, now, pharmaceutical companies.

The undercover report has yet to gain significant coverage in mainstream media, and Pfizer has not responded publicly.

https://www.themainewire.com/2023/01/pfizer-director-of-research-spills-virus-vaccine-secrets-in-project-veritas-undercover-video/

Video at:  https://twitter.com/Project_Veritas/status/1618405890612420609

TMEM161B modulates radial glial scaffolding in neocortical development

Wang L, Heffner C, Vong KI, Barrows C, Ha YJ, Lee S, Lara-Gonzalez P, Jhamb I, Van Der Meer D, Loughnan R, Parker N, Sievert D, Mittal S, Issa MY, Andreassen OA, Dale A, Dobyns WB, Zaki MS, Murray SA, Gleeson JG. TMEM161B modulates radial glial scaffolding in neocortical development. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2209983120. doi: 10.1073/pnas.2209983120. Epub 2023 Jan 20. PMID: 36669109.

Abstract

TMEM161B encodes an evolutionarily conserved widely expressed novel 8-pass transmembrane protein of unknown function in human. Here we identify TMEM161B homozygous hypomorphic missense variants in our recessive polymicrogyria (PMG) cohort. Patients carrying TMEM161B mutations exhibit striking neocortical PMG and intellectual disability. Tmem161b knockout mice fail to develop midline hemispheric cleavage, whereas knock-in of patient mutations and patient-derived brain organoids show defects in apical cell polarity and radial glial scaffolding. We found that TMEM161B modulates actin filopodia, functioning upstream of the Rho-GTPase CDC42. Our data link TMEM161B with human PMG, likely regulating radial glia apical polarity during neocortical development.

COVID vaccine issue

Docket No. FDA-2021-N-1088 for “Vaccines and Related Biological Products; Notice of Meeting  

Please read the attached document "FDA Comment Maddie de Garay" regarding her adverse reaction to the Pfizer Covid Vaccine during the trial for 12-15-year-olds at Cincinnati Children's Hospital where she was also treated and our request to not approve the EUA for 5-11 year olds based on our daughter Maddie's severe adverse reaction to the Pfizer Covid Vaccine during the trial. I also included supporting documents to prove she was in the trial and got the actual vaccine. 

Our daughter Maddie was a healthy, energetic, 12-year-old social butterfly with an infectious sense of humor who loved school, trying new things, and hanging out with her friends. She wants to be a pediatric nurse when she grows up. She volunteered for the Pfizer Covid Vaccine Trial for 12-15-year-olds at Cincinnati Children’s with her 2 older brothers and was excited to be able to help other kids get out of this pandemic. She received her first dose on 12/30/21 and had the expected side effects which were no cause for concern. She got her second dose on 1/20/21 and less than 12 hours later she experienced severe abdominal pain, painful electric shocks on her spine and neck, swollen extremities, ice-cold hands and feet, chest pain, tachycardia, pins and needles in her feet that eventually led to the loss of feeling from her waist down. She had blood in her urine from 7 tests over 3 months, mysterious rashes, peeling feet, reflux, gastroparesis, vomiting, and eventually the inability to swallow liquids or food, dizziness, passing out, convulsions, the inability to sweat, swollen lymph nodes in her armpits, urinary retention, heavy periods with clots of blood, decreased vision, tinnitus, memory loss, mixing up words, extreme fatigue, and sadly more. She spent 64 days in the hospital, had 3 hospital stays, and 9 trips to the ER. We are 9 months into this, we have no real answers. She is trapped in a body that doesn’t work remotely close to the way it did before.  

Her days now look like this...she is in a wheelchair with an ng tube and has to do 5 feeds, 4 water boluses and take multiple medications each day. She goes to school for 2 hours a day, which is all she can handle. She has 2 or more doctor’s appointments every week and needs help with simple things like showers, opening car doors, and lifting things. Somehow she still has her infectious sense of humor, hangs out with friends, and has more resilience than I ever had at her age.  

We emailed and called many times to Cincinnati Children's Hospital Dr. Robert Frenck, the principal investigator for the Pfizer Trial for 12-15-year-olds, and asked what was reported to VAERS for Maddie’s reaction to the vaccine. After being dismissed and not responded to for weeks, he then told us they do not report adverse reactions to VAERS during the trial, they report them to Pfizer who then reports to the FDA. When we asked him to tell us what was reported, the best answer he gave us was everything was reported. We asked for clarification on what symptoms/reactions had been reported so we didn’t duplicate on our submission to VARES, but he refused to give any details other than they had been reported to their sponsor (Pfizer). The only adverse reactions disclosed in the EUA were functional abdominal pain and paresthesia. How do we know all of her adverse reactions were reported? Why weren’t ALL of the other adverse reactions she had disclosed in the EUA? How can we find out specifically what was reported to Pfizer and then to the FDA? No one from the FDA, CDC, NIH, or Pfizer ever contacted us to discuss what happened to Maddie, NO ONE! Maddie received all of her treatment at Cincinnati Children’s Hospital, we thought and were assured she would receive the best care if we took her there. That was the biggest mistake we ever made. Why hasn’t Maddie's case been researched by the NIH, like several other vaccine injured people that had almost identical reactions? Why wasn’t she researched to determine why this happened to her so more healthy children weren’t injured? Why was her diagnosis changed to Functional Neurological Disorder shortly after Dr. Frenck collaborated with another party who had only talked to her twice via televisit for less than two hours total and one day (4/8/21) before Pfizer submitted for the EUA for 12-15 year olds? Why did they say they would pay her medical bills related to the vaccine reactions, but instead led us on for months, and finally said this is not related and they would not pay? They ended up sending us paperwork to fill out for Medicaid which thank God she was finally approved for.  

We trusted Pfizer and the government when they said the vaccine was safe and if Maddie was one of the rare cases that had a reaction, she would get the best care possible. There are thousands of adults and children experiencing the same adverse reactions as Maddie after getting the Pfizer covid vaccine. Because she wasn’t thoroughly researched and information was not provided in the EUA, people are not getting accurate informed consent when they get the vaccine and sadly are suffering the same consequences with no help from the medical community. I cannot even keep up with messages people send me saying this happened to them or their child, this isn’t anything I would have ever imagined in a million years would happen to me or anyone in the United States. We have been living a nightmare, Maddie’s life was forever changed and she has been brushed aside as collateral damage. Let me repeat that, a 13 year old is collateral damage. Maddie volunteered to help get this vaccine approved, she did the right thing and she was excited to do it. Now it is time for you to do the right thing so she can get her life back and so more healthy children and adults don’t have their lives ruined by this vaccine. I am begging you to research why this happened to Maddie and to not approve the EUA for 5-11-year-olds until you figure out why. If it is something pre-existing then figure it out so anyone else that has it can be exempt from getting this vaccine. That was never done. You are putting healthy children like Maddie at risk for having life altering adverse reactions and in some cases even losing their lives. I am attaching documentation to provide proof that she was in the Pfizer Trial for 12-15-year-olds at Cincinnati Children’s Hospital and that she did get the vaccine and not the placebo. If you need documentation or proof for anything else, we will be happy to provide it to you. We have nothing to hide.  

Sincerely, Stephanie de Garay and Patrick de Garay (Maddie de Garay’s mother and father) 

https://www.regulations.gov/comment/FDA-2021-N-1088-129763

Diagnosis and management of functional tic-like phenomena

Malaty IA, Anderson S, Bennett SM, Budman CL, Coffey BJ, Coffman KA, Greenberg E, McGuire JF, Müller-Vahl KR, Okun MS, Quezada J, Robichaux-Viehoever A, Black KJ. Diagnosis and Management of Functional Tic-Like Phenomena. J Clin Med. 2022 Oct 31;11(21):6470. doi: 10.3390/jcm11216470. PMID: 36362696; PMCID: PMC9656241  

 

Over the past 3 years, a global phenomenon has emerged characterized by the sudden onset and frequently rapid escalation of tics and tic-like movements and phonations. These symptoms have occurred not only in youth known to have tics or Tourette syndrome (TS), but also, and more notably, in youth with no prior history of tics. The Tourette Association of America (TAA) convened an international, multidisciplinary working group to better understand this apparent presentation of functional neurological disorder (FND) and its relationship to TS. Here, we review and summarize the literature relevant to distinguish the two, with recommendations to clinicians for diagnosis and management. Finally, we highlight areas for future emphasis and research.   

   

From the article:    

 

The growing number of people with sudden onset tic-like phenomena typically do not manifest the usual tic symptoms and patterns. Instead, they often demonstrate the sudden onset of complex motor and vocal tic-like phenomena that differ substantially from those typically seen in youth with TS.   

 

Functional tic-like symptoms seen in recent years primarily occur in adolescents, and females appear to be at higher risk. They usually do not have an identified or family history of tics, though one needs to be thoughtful about a potential history of tics that went undiagnosed.   

 

The growing number of people with sudden onset tic-like phenomena typically do not manifest the usual tic symptoms and patterns. Instead, they often demonstrate the sudden onset of complex motor and vocal tic-like phenomena that differ substantially from those typically seen in youth with TS.   

   

These individuals often have been experiencing co-occurring anxiety or depression and significant psychosocial stressors. Interestingly, there is preliminary evidence that in some patients, pre-existing tics and TS may be a predisposing factor for the development of rapid-onset functional tic-like behaviors.   

 

Some patients recapitulate features encountered in a skewed social media representation of tics. In three studies, expert tic clinicians reviewed popular social media videos seen by many of the abrupt-onset cases, and concluded that “TS symptom portrayals on highly viewed TikTok videos are predominantly not representative or typical of TS”. Portrayals were heavily skewed for environmentally responsive, aggressive, self-injurious or throwing behaviors and coprolalic utterances. Not surprisingly, therefore, tic-like behaviors developing “after social media consumption differ from tics in Tourette’s syndrome, strongly suggesting that these phenomena are categorically different conditions".  

 

However, the quality of the evidence for which clinical features can accurately differentiate functional tic-like symptoms from TS varies, and some features are less useful in diagnosing individual patients, as discussed in the next sections.     

 

Early in the upsurge of cases in the past few years, many clinicians noted marked differences between them and the perhaps hundreds of tic patients they had evaluated previously. Such evidence should not be ignored, but potentially is vulnerable to bias and susceptible to differences in exposure of the clinician. Later reports compared specific features between groups of typical and FND tic patients, sometimes with prospective ascertainment. However, in many cases the diagnostic approach used to divide the groups presumably used some of the same features, such that the results may be criticized as possibly circular. For instance, if clinicians expected to see more FND in female patients, and explicitly or implicitly included sex in their clinical diagnostic approach, they would potentially classify more females in the clinical FND groups. Of note, there has not been a clear and consistent definition of functional tics used consistently across studies, and expert clinician impression is typically relied upon.   

 

Fortunately, some more recent studies have incorporated strategies to address these limitations. For instance, in some such studies, expert clinicians blind to clinical diagnosis reviewed symptoms in groups identified by other clinicians . Other studies prospectively ascertained clinical features of clinical groups defined by a single criterion chosen a priori (e.g., rapid onset)...  

 

Recent reviews discuss recommendations for clinical assessment and quantification of motor FNDs. Thorough assessment, including attention to the biopsychosocial model, is the first step in clarifying the presenting diagnosis. The clinician should ask the patient about symptom phenomenology, onset, and progression. The patient should also be screened for co-occurring disorders, including depression, anxiety, and adjustment disorders, asked about a history of any other FND, and asked about any recent stressors, including traumas (though it is important to note a traumatic event is not needed in order to have symptoms consistent with FND). The patient should be asked about exposure to “Tourette” videos on social media or other internet sites; however, this too should be taken within the greater context of symptoms. In addition, one should ask about the patient’s and family’s history of tics (even if subtle, or previously subsided) and of commonly co-occurring disorders, including ADHD and OCD. Finally, outside of the particular tic-like symptoms themselves, it is important to assess the functional impairment incurred from the symptoms, including the impact on other physical and psychological factors, including quality of life, as this information can help to inform treatment...   

 

Varying Diagnostic Utility of Clinical Features. The list in Table 1 takes into account the varying quality of evidence listed above, and suggests features common to functional tic-like behaviors that may help to distinguish FND from TS when taken together in a comprehensive clinical evaluation. However, most of these features are of little use in isolation. At the top of the list appear features that differ significantly in prevalence within FND vs. typical tic disorders, but that are not very useful in isolation with regard to differential diagnosis. For instance, anxiety is more common in FND than in TS, but it is common enough in TS that its presence gives little differential diagnostic information. At the bottom of the list appear features that individually produce a high posterior probability of FND. For instance, coprolalic utterances at onset are very common in FND-related tic presentations, while specific complex vocal tics such as coprolalia are quite rare at the onset of typical tic disorders. Importantly, the clinician rarely has to rely on a single feature to make a diagnosis. Thus when formulating whether the symptoms are more consistent with a primary tic disorder, a functional movement disorder or both, it is important to understand the complexity of symptoms as a whole and in the overall context of the presentation. Similarly, it is helpful to evaluate the symptoms over a period of time rather than using a clinical snapshot to make the determination. The combination of numerous features from Table 1 makes the diagnosis more confident; an example might be abrupt onset of severe tic-like movements in the limbs, plus ten different non-suppressible, long, socially inappropriate sentences, in a 17-year-old girl with no prior tics, after social media exposure to identical symptoms. The entire constellation of symptoms, time course, and context are considered in approaching diagnosis. 

Table 1

Features of relevance to differentiating FND from TS.

Features near the top of the list are more common in FND than in TS, but are seen in TS as well, and are not diagnostic in isolation. Features may not be unique to either condition, nor prerequisite, but are more commonly present. Features near the bottom of the list strongly suggest FND.

Anxiety (higher prevalence) Female predominance (greater proportion of affected individuals) No family history of tics, OCD or ADHD No personal history of OCD, ADHD, or earlier typical tic disorder No urge to tic or premonitory sensation (some young children do not report urges or premonitory sensations) Onset in the mid-teen years Significant variability of tic symptoms (vs. stereotyped tics) No response, or atypical response, to proven tic-suppressing medications Symptoms in extremities before face and neck (lack of typical rostrocaudal progression) Symptoms that dramatically and persistently disrupt the person’s intended actions or communications Symptoms that the patient has not previously experienced that closely replicate those of someone whom the patient has observed Extreme “attacks” of tic-like behavior—discrete episodes of complex movements and/or vocalizations, lasting from minutes to several hours with an abrupt onset and offset, often described as appearing to be “seizure-like” and often early in the course. Inability to suppress, even temporarily Severity of movements and vocalizations is constant over time rather than waxing and waning Movements or vocalizations that are dramatically more severe in the presence of others versus when alone Onset in adulthood Presence of other functional neurological symptoms Sudden, abrupt onset Severe symptoms at onset Coprophenomena at onset Lack of perceived agency (a sense that the movement is done to the patient rather than by them) Tics involving the body or limbs without a history of tics involving the eyes, face, and head

Nevertheless, we acknowledge that some individual cases may be difficult to classify, and in such cases, diagnostic humility is justified pending further information. Examples may include patients with typical TS in childhood, then few tics for 5 years, followed in late adolescence by an abrupt recrudescence of severe tics with some unusual features. Some such patients may have TS, while others may have both TS and FND...  

 

Delivering an accurate diagnosis of FND is critical to avoid the risk of unneeded medical interventions. Specifically, antipsychotic and immunomodulatory therapies have no role in managing FND, unless other diagnoses require them.  Brain imaging, electroencephalogram (EEG), and blood work are usually not necessary. They can be harmful as they may introduce ambiguity and confusion regarding the diagnosis and may inadvertently reinforce the state of perceived illness. However, if specific clinical features merit work-up, the clinician may judiciously order investigations in a targeted fashion.   

   

The optimal multidisciplinary treatment for FND has not been standardized.   

 

Most experts believe that with early diagnosis and intervention, the prognosis is good and full recovery is possible. Appropriate counseling about the nature of the diagnosis is key. Although we must acknowledge that some individuals may manifest both TS exacerbations and FND, differentiating the treatment of tics and TS from that of FND is important. In individuals who have relapsing or persistent symptoms, a multi-disciplinary approach is likely the best strategy...   

 

The first priority in managing FND is education. This includes making a confident, specific diagnosis using the words “functional neurologic disorder” when the diagnosis is clear. It is important to explain that FND can be completely distinct from TS, although the outward features may be similar. An article by Carson et al. (2016) provides helpful and practical tips for communicating the diagnosis effectively, and a video describes for clinicians a neuroscience-based approach to delivering an FND diagnosis. Explaining how the diagnosis is made and why potentially harmful additional tests are not needed is often necessary. The patients should be counseled that while medications are generally not helpful in this condition (aside from treating comorbid mood or anxiety disorders), treatment with a combination of psychology and other therapy services often is very effective at reducing and/or completely resolving symptoms.   

 

Individuals and their supporting caregivers or partners should be educated and offered resources to learn more. Specific resources that can be helpful are neurosymptoms.org (regarding FND in general) and its content specific to functional tics (https://www.neurosymptoms.org/en_GB/symptoms/fnd-symptoms/functional-tics/, accessed on 21 October 2022), the TAA statement that addresses this topic in lay language (https://tourette.org/rising-incidence-of-functional-tic-like-behaviors/, accessed on 21 October 2022), and a website that links several resources specifically for the current epidemic of functional tic-like behaviors (https://cumming.ucalgary.ca/resource/tourette-ocd/children-and-adults/disorder-specific-resources/tourette-syndrome-and-0) (accessed on 21 October 2022)...   

 

There are frequently personal or environmental influences that can increase the expression of functional tic-like behaviors. While some may be predictable across many people with FND, others are personal and individual factors. Thus it is critical for a clinician to help identify (and ultimately reduce) exacerbating factors.   

 

Some models for understanding rapid onset functional tic-like behaviors suggest that predisposing traits may include genetic factors, early life events, introspective awareness, and social cognitive traits. Acute contributions can include psychosocial stressors (e.g., anxiety, and depressed mood), social isolation, and life stressors (e.g., abrupt transitions in educational programs and/or academic demands). Exposure to tic-like behaviors in this context may lead to developing those same behaviors. Increased attention following complex tic-like behaviors and related avoidance of stressful circumstances (such as school) may inadvertently reinforce and increase the frequency of these symptoms. Considering this model, identifying triggers that may provoke FND manifestations is a critical step.   

 

For some young people, engaging with social media content related to tic manifestation, such as watching videos of highly visible personalities with tics and tic-like behaviors, may provoke similar manifestations. This phenomenon shares some similarity with the well-known experience in primary tic disorders that discussing or thinking about tics may increase the likelihood they occur. More time watching social media was significantly associated with greater tic severity and lower quality of life, even though 95% of the teens with tics surveyed did not search for tic content online. In functional tic-like behaviors, the role of social media has been suspected to be especially impactful.   

 

Understandably, social media has become a cornerstone of social interaction for many young people. As such, many young people may interact with social media content that can influence the expression of tics and/or tic-like behaviors. In cases in which social media content is exacerbating and/or worsening tics and/or tic-like behaviors, it would be prudent to reduce access to social media (along with other factors that exacerbate symptom expression) for a period of time. As patients learn skills to effectively manage tics and tic-like behaviors in treatment, access could be reintroduced in a graduated manner.   

 

Personal stressors can be critical to explore. Research in non-epileptic seizures has shown an increased incidence of past abuse as compared with epilepsy patients, and adverse life events have been proposed as a potential contributing factor to the development of FND. It is important to emphasize that there is often a delay between adverse events and the development of functional symptoms. Stressors may include sleep deprivation, in which case addressing sleep hygiene and routines is advisable. Furthermore, if significant stressors are not apparent, it is important to emphasize that ongoing “normal” stresses of life may contribute. Physiological arousal, including disrupted sleep or signs of anxiety, may support such a conclusion. Counseling to explore the impact of life circumstances and to learn to recognize and manage stress is critical, and may be one of the most important aspects of management. It should be noted that not all FND cases have stress or adverse events as a contributing factor, and the absence of an obvious trigger should not preclude the diagnosis.   

 

The occurrence of functional tic-like behaviors often has an impact on school, personal, or professional life. It is important to balance nurturing support and empathy, which are appropriate, against inadvertently reinforcing the symptoms by allowing avoidance of stressful but necessary aspects of life. The goal should be to develop skills to cope with the functional tic-like behaviors while simultaneously working to reduce or eliminate the symptoms.   

 

While these functional tic-like symptoms, like other FND symptoms, are not intentional, there may be some unintentional reinforcement or secondary gain in some patients. Exploring that possibility can help identify possible interventions to reduce the symptoms...   

 

When a person with functional tic-like behaviors also suffers from additional conditions, such as anxiety, depression or insomnia, it is critical to identify and address those co-occurring conditions through behavioral therapy and/or medication. Addressing these important contributing factors makes resolving functional disorders more likely...   

 

It is often helpful to describe the process of treating the symptoms as “retraining the brain.” In addition to psychology to help identify possible triggers, this process can be augmented with physical, occupational and/or speech therapy. While the specific treatment regimens will differ depending on the patient and specific abnormal movements or sounds, the overall goals should be to reinforce normal motor patterns and redirect the unwanted movements or sounds. A key is to reestablish a sense of control over these movements and sounds.  

  

While Comprehensive Behavioral Intervention for Tics (CBIT) was developed and validated for the treatment of tics in TS and has not been extensively studied in functional tic-like behaviors, there have been some reports that a modified CBIT program can be helpful. Proposed modifications include focusing more on functional behavioral assessment components, such as exploring the internal and external antecedents of the tic-like behaviors and exploring the consequences that the behaviors induced.   

 

While studies specifically on functional tic-like behaviors are not available, there is good reason to think that Cognitive Behavioral Therapy (CBT) or psychodynamic psychotherapy may also help. It has been proposed that motivational interviewing and CBT can help reduce stress, address anxiety and comorbidities, and improve adaptive functioning. Evidence for pharmacotherapy in the absence of co-occurring conditions is limited.   

 

In summary, treatment must be individualized. A treatment strategy should ideally include education on the nature of FND, avoiding interventions and treatments not indicated, and avoiding triggers as well as exacerbating factors. CBT for FND may be recommended and helpful. Careful avoidance of reinforcing the symptoms is critical. CBIT offers a well-studied model to reduce tics, reduce reinforcement of tics and tic-like behaviors, and may be useful for other functional movement symptoms. Addressing depression or anxiety, when present, and optimizing sleep comprise an additional and important component of care.